Investigating lung injury after subarachnoid hemorrhage
Relationship Between Acute Lung Injury and Pulmonary Hyaluronic Acid Deposition After Subarachnoid Hemorrhage
This study looks at how lung injury happens after a brain bleed to see if a substance called hyaluronic acid plays a role and to find better treatments for patients aged 18 to 80.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 24 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Tianjin Medical University Academic / other |
| Locations | 1 site (Tianjin) |
| Trial ID | NCT06628531 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the mechanisms behind acute lung injury (ALI) that occurs following subarachnoid hemorrhage (SAH). It focuses on understanding the role of hyaluronic acid accumulation in the lungs and its relationship with the pathological progression of lung injury. By examining patients diagnosed with SAH, the study seeks to identify potential therapeutic strategies to improve patient outcomes. The research will involve patients aged 18 to 80 who meet specific inclusion criteria, allowing for a detailed analysis of the condition.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 80 diagnosed with subarachnoid hemorrhage within the last 5 days and exhibiting a Hunt-Hess scale of IV or V.
Not a fit: Patients with a history of traumatic brain injury, lung infections, or other significant health issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for patients suffering from lung injuries related to subarachnoid hemorrhage.
How similar studies have performed: While the specific mechanisms of lung injury after SAH are not well-studied, related research on pulmonary injury and hyaluronic acid has shown promise in other contexts.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age between 18 and 80 years old with independent behavior ability or authorized legal representative. * A documented diagnosis of SAH within 5 days. * A Hunt-Hess scale of Ⅳ or Ⅴ. * Absence of clinical and etiological evidence of pulmonary infection. Exclusion Criteria: * Pregnant or lactating women. * Present history of traumatic brain injury or intracranial hemorrhage. * Past history of neurological disorders, lung infection within the past six months, cancer, chronic cardiopulmonary diseases, hematological diseases or renal failure. * Have participated in clinical trials in the past 4 weeks. * The investigator considers that not appropriate for inclusion.
Where this trial is running
Tianjin
- Tianjin Medical University General Hospital — Tianjin, China (Recruiting)
Study contacts
- Principal investigator: Yadan Li — Tianjin Huanhu Hospital
- Study coordinator: Xintong Dr. Ge
- Email: xge@tmu.edu.cn
- Phone: 86-13662055012
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.